Introduction
Chlamydia trachomatis is one of the main causative microorganisms of sexuallytransmitted diseases (STD) and has been spreading rapidly in recent years, creating serious problems clinicallyl).
Although C. trachomatis infection can be primarily diagnosed by detection of antigens, antigen detection is not easy in pelvic inflammatory disease, prostatitis and epididymitis. Therefore, clinical diagnosis often depends on measuring antibody titers in serum or secretions from infected areas2, 3, 4) .
Sampling of specimens from infected areas is difficult initially even in suspected cases of infection. Therefore, screening tests which measure serum antibody titers may be useful in convincing patients to undergo further clinical tests.
Conventional methods, such as the microimmunofluorescence (micro-IF) method5), microplate immunofluorescence antibody technique (MFA)6), and indirect immunoperoxidase assay (IPAzyme(R)) method7), however, require complicated procedures, do not permit measurement of large numbers of specimens simultaneously, and are not objective because they are evaluated visually. These shortcomings have often been pointed out8).
In order to solve these practical problems, HITAZYME(R)(Hitachi Chemical Co.,Ltd.), a new test kit for measuring C. trachomatis antibody by the enzyme immunoassay method (EIA), hasbeen developed. HITAZYME(R) allows objective quantification of large numbers of samples. This method makes use of chlamydial outer membrane complex purified from the elementary body (EB) of C. trachomatis L2 strain as fixed antigen. Anti-Chlamydia antibody titers in specimens can be measured bymeans of their optical density9).
We investigated the C. trachomatis antibody-positive rate in patients with genitourinary tract infections (including pregnant housewives). Here we report our clinical assessment of this test kit. previously diluted with binding buffer for 2 hours. After incubation, it was washed with washing buffer five times, and incubated with 0.05% 3,3'-diaminobenzidine tetrahydrochloride(DAB) and Trissaline buffer solution containing 0.05% H202. When a color developed, the reaction solutionwas discarded, the blot was washed with distilled water and then air dried. The color of the samples was evaluated in comparison with a negative control and a positive control.
Results

Determination of the Normal Range (Cut-off Values)
The distribution of serum IgA and IgG values (determined by HITAZYME(R)) in 258healthy adults is shown in Fig. 2 . All patients were antibody-negative using IPAzyme(R).
The mean IgA antibody titers was 0.083 with a standard deviation of 0.047, and the mean IgG antibody was 0.052 with standard deviation of 0.047, and the mean IgG antibody was 0.052 with standard deviation of 0.037.
When specimens from 258 healthy adults were assayed with HITAZYME(R), the distribution of IgA and IgG antibodies was shifted to right. Hence, Geary's normal distribution test10 was conducted after excluding extreme values. Since a normal distribution was seen after excluding only a small percentage of the samples, the normal distribution was determined using the rest of the samples. The cut-off value (normal range) was the mean plus 2 X S.D. (standard deviation). We conducted the following investigations. (Table 1) All 1109 patients were assayed using HITAZYME(R) (enzyme immunoassay method, EIA) and IPAzyme(R) (indirect immunoperoxidase assay), and the data were compared.
Comparison of HITAZYME(R) and IPAzyme(R) 1) Comparison of Antibody Values
Agreement between two assays for IgA was 82.6% (916/1109), and relatively good agreement was achieved. However, 5.5% (61/1109) were HITAZYME(R)(-), IPAzyme(R)(+), while 11.9% (132/1109) were HITAZYME(R)(+), IPAzyme(R)(-). Thus, the results for quite a few patients disagreed. In these cases, more specific Western blot analysis was performed to check the reactivity of and-C. trachomatis antibody.
Agreement between the two assays for IgG was 73.3% (817/1109). Agreement was relatively low, 24.4%
(271/1109) were HITAZYME(R)(-), IPAzyme(R)(+), comprising most of the cases of disagreement. In these cases, more specific Western blot analysis was performed to check the reactivity of and-C. trachomatis The IgG antibody-positive rate in antigen(+)cases was 63.6% (7/11) with HITAZYME(R), and 72.7% (8/11) with IPAzyme(R), while in antigen(-)cases it was 33.3% (6/18) using HITAZYME(R) and 33.3% (6/18) using IPAzyme(R). No statistical significance was detected in any of these instances because of the small number of cases. We need to increase the number of cases.
In female patients, the IgA antibody-positive rate in antigen (+) cases was 68.2% (103/151) with HITAZYME(R) and 58.3% (88/151) with IPAzyme(R), and while in antigen(-)cases the rates were 15.8% (147/929) and 12.5% (116/929), respectively. Therefore, the IgA antibody-positive rate in antigen (+) cases was significantly higher than in antigen(-)cases (p<0.01).
The IgG antibody-positive rate in antigen (+) cases was 75.5% (114/151) with HITAZYME(R) and 88.1%
(133/151) with IPAzyme(R), while among antigen(-)cases is was 15.5% (144/929) with HITAZYME(R), and 40.5% (376/929) with IPAzyme(R). The two assays were comparable in antigen (+) cases. The IgG antibodypositive rate in antigen (-) cases was significantly higher using IPAzyme(R) (p<0.0l). This may have been 3) IgG Antibody-positive Rates According to Disease (Fig. 6 ) In male urethritis alone, no significant difference in percentage of IgG (+) cases was detected among antigen (+) patients and antigen (-) patients. The IgG antibody-positive rate was significantly (p<0.01) higher in antigen (+) cases than antigen (-) cases in all other diseases.
However, even among male urethritis patients in which antigen detection is relatively easy, approximately 30% of antigen (-) patients were positive for IgG antibody, suggesting that IgG antibody was elevated due to previous infections or considerable number of cases were false-positive due to cross-reactions.
C. trachomatis Antigen-positive Rates According to Group Classified by Antibody Findings
In the previous sections, antibody-positive rates were investigated on the basis of antigen-positive findings, whereas in this section, the antigen-positive rates were investigated on the basis of antibodypositive findings. 1) Male Urethritis (Fig. 7 ) Considerable variability can be seen probably because only 29 patients were tested. In the IgA (+), IgG (+) group, 63.6% of the patients were positive for antigen with HITAZYME(R), and 40.0% of the patients were positive for antigen with IPAzyme(R). Eight out of 11 antigen (+) patients were positive for IgA antibody with HITAZYME(R), but only 2 out of 11 antigen (+) patients were positive for IgA antibody with IPAzyme(R). Therefore, HITAZYME(R) reveals the activity of infection better than IPAzyme(R).
2) Pregnant housewives (Fig. 8) In the IgA (+) IgG (+) group, the antigen-positive rate was 38.6% with HITAZYME(R)and 35.9% with IPAzyme(R), and significantly higher than the 1.4% with HITAZYME(R) and 1.9% with IPAzyme(R) in the IgA (-) IgG (-) group. Moreover, when either IgA or IgG was positive, 86.6% of antigen (+) cases can be detected. Therefore, antibody tests are useful as screening tests.
3) Cervicitis (Fig. 9 ) In the IgA (+), IgG (+) group, the antigen-positive rate was 60.3% with HITAZYME(R) and 61.2% with IPAzyme(R), both the which were high values. In any event, whether either IgA or IgG is positive, most of antigen (+) cases can be detected. (Fig. 10) In the IgA (+), IgG (+) group, the antigen-positive rate was 56.0% with HITAZYME(R) and 50.0% with IPAzyme(R). Since it is difficult to detect antigen in pelvic inflammatory disease cases, the actual number of cases of C. trachomatis infection may be even higher. Since antibody test data are so useful in making a diagnosis, in IgA (+), IgG (+) group, the possibility of having C. trachomatis infections may be higher even if antigen-negative. Discussion C. trachomatis infections have been causing serious problems in Japan, since the disease has been spreading very rapidly. Consequently, developments in the diagnosis and prevention of the disease have been greatly anticipated. C. trachomatis infection often produces relatively mild symptoms, and many female patients in particular have asymptomatic infection. Therefore, it is nearly impossible to convince patients to collect genitourinary tract specimens themselves when asymptomatic, even among high risk people. Under these circumstances, the only possible way is to perform antibody tests. Our data did not prove that antibody (+)=antigen (+). Nevertheless, antibody tests are meaningful as screening tests because of their high correlation with antigen tests.
Additionally, even when samples can be obtained from the genitourinary tract of symptomatic patients, it is often difficult to detect antigen in cases of pelvic inflammatory disease, prostatitis and epididymitis. Therefore, antibody tests on secretions or serum may often corroborate the diagnosis. In the past, the main assay methods for C. trachomatis antibody were the microimmunofluorescence (micro-IF) method5), microplate immunofluorescence antibody technique (MFA)6), and indirect immunoperoxidase (IPAzyme(R)) method7).
The micro-IF method') is an indirect immunofluoresecence antibody method developed by Wang et al. in 1970. It utilizes C. trachomatis elementary body as the antigen, and is an excellent method in terms of sensitivity and specificity. It can determine immunotypes and requires a great deal of work to prepare the antigens because of their variability. It also requires special skills and facility in evaluating the data. Hence, it is not suitable as a clinical test.
The MFA method6) is an indirect immunofluorescence antibody method developed by Matsumoto et al. Since it utilizes inclusion bodies in cells infected with C. trachomatis as the antigen, it is not necessary to purify the antigen. It can be evaluated under a low magnification microscope. The problems are crossreactivity with antibody against C. psittaci and C. pneumoniae, because of the use of C. trachomatis infected cells, and lack of objectivity because the results depend on visual evaluation8).
IPAzyme(R) 7) is a commercially available test kit which is based on an indirect immunoperoxidase method. Although it has been the most widely used method in Japan, since it also utilizes C. trachomatis 1.2 strain infected cells as antigen, it has the same problems as the MFA method, i.e., cross-reactivity with antibodies against C. psittaci and C. pneumoniae, and lack of objectivity in evaluation. Therefore, development of simpler, more sensitive and specific assays for C. trachomatis antibodies had been highly anticipated.
Since this new test kit, HITAZYME(R), utilizes Chlamydial outer membrane complex purified from C. trachomatis L2 elementary body as the solid phase antigen, it seldom cross-reacts with antibodies against C. psittaci or C. pneumoniae. Since it is based on an EIA method, the results can be evaluated semiquantitatively by measuring optical density. Thus, HITAZYME(R) is a more objective and quantitative assay capable of processing many samples.
We therefore assessed this test kit for C. trachomatis antibodies. On the other hand, since IPAzyme(R) utilizes L2 strain-infected cells as antigen, lipopolysaccharide (LPS, a genus-specific antigen) and reticulate body (RB) in inclusion bodies which has genus-specific antigenicity increase cross-reactivity with C. pneumoniae, C. psittaci, and this may explain the disagreement mentioned above.
[Antibody-positive Rates in Antigen (+) Cases] The IgA antibody-positive rate in antigen (+) cases was significantly (p<0.01) higher than in antigen (-) cases except for male urethritis (IPAzyme(R)). Therefore, IgA antibody reflects the activity of infection as an acute antibody. There are some cases, however, in which IgA antibody is positive and antigen is negative, and in which IgA antibody is negative and antigen is positive.
This type of disagreement can be explained as follows. In antigen (+), IgA antibody (-) cases, the infection is in its initial phase, and IgA antibody has not increased yet. In antigen (-), IgA antibody (+), cases, the infection has taken place in superior regions, and consequently no antigen is detected in the urethra or cervical canal, the amount of antigen in the infected areas was small, or specimens were collected improperly.
In contrast, IgG antibody was approximately 30 to 60% positive in antigen (-) cases, and was correlated with a post history of C. trachomatis infection. IgG antibody is not suitable as an indicator for active infection.
[C. trachomatis Antigen-positive Rates According to Groups Classified by Antibody Findings] Generally, it is more difficult to detect antigen in female patients than male patients because specimens cannot be collected properly due to mucous discharge in the cervical canal, the fact that the antigen detection rate varies despending on the menstrual cycle, and that C. trachomatis travels superiorly, and so it may not be present in cervical canal in pelvic inflammatory diseases. Therefore, antibody tests are particularly useful in female cases. Antigen tests may not be sufficient for the diagnosis of C. trachomatis infection, and serum antibody tests should be performed at the same time. A diagnosis should be made on the basis of all these clinical data.
Nevertheless, even among female patients at high risk, it is not possible to perform sampling in every patient. In female patients, as shown in Figures 8,9 and 10, when either IgA antibody or IgG antibody is positive, and particularly in those who are IgA (+), IgG (+), approximately 40 to 60% of patients were antigen-positive. When both IgA antibody and IgG antibody were negative, only 1 to 10% of cases were antigen-positive. Therefore, antibody tests should be performed first. If antibody tests prove positive, antigen tests should be performed. This diagnostic protocol may be useful clinically as a screening method for C. trachomatis infection.
